BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Implanon NXT®: Possible risks and complications associated with insertion, localisation, removal and migration

2016.06.27

Active substance: etonogestrel

The company MSD Sharp & Dohme GmbH recommends that only those physicians should insert and remove Implanon NXT® who have completed training for the use of the NXT® applicator and techniques for insertion and removal of the Implanon NXT® implant.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 1MB, File does not meet accessibility standards

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK